Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- LQDA
- Price
- 41.07
- Stock movement up
- +1.08 (2.71%)
- Company name
- Liquidia Technologies Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.57B
- Ent value
- 3.67B
- Price/Sales
- 51.62
- Price/Book
- 162.02
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 17.43
- PEG
- -
- EPS growth
- -8.44%
- 1 year return (CAGR)
- 201.54%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LQDA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 51.62 |
| Price to Book | 162.02 |
| EV to Sales | 53.01 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 87.00M |
| EPS (TTM) | -1.41 |
| FCF per share (TTM) | -1.25 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 69.22M |
| Gross profit (TTM) | 61.88M |
| Operating income (TTM) | -107.27M |
| Net income (TTM) | -121.85M |
| EPS (TTM) | -1.41 |
| EPS (1y forward) | 2.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.40% |
| Operating margin (TTM) | -154.98% |
| Profit margin (TTM) | -176.04% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 157.50M |
| Net receivables | 35.96M |
| Total current assets | 226.72M |
| Goodwill | 3.90M |
| Intangible assets | 2.99M |
| Property, plant and equipment | 31.54M |
| Total assets | 275.98M |
| Accounts payable | 6.02M |
| Short/Current long term debt | 199.18M |
| Total current liabilities | 102.94M |
| Total liabilities | 253.93M |
| Shareholder's equity | 22.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -100.74M |
| Capital expenditures (TTM) | 7.09M |
| Free cash flow (TTM) | -107.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -552.55% |
| Return on Assets | -44.15% |
| Return on Invested Capital | -56.57% |
| Cash Return on Invested Capital | -50.06% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 40.06 |
| Daily high | 42.46 |
| Daily low | 39.51 |
| Daily Volume | 2.05M |
| All-time high | 41.07 |
| 1y analyst estimate | 44.00 |
| Beta | 0.48 |
| EPS (TTM) | -1.41 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| LQDA | S&P500 | |
| Current price drop from All-time high | -1.58% | -2.53% |
| Highest price drop | -73.59% | -19.00% |
| Date of highest drop | 18 Nov 2024 | 8 Apr 2025 |
| Avg drop from high | -48.83% | -2.49% |
| Avg time to new high | 107 days | 6 days |
| Max time to new high | 315 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.57B
Marketcap category
Mid-cap
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Employees
170
Website
Investor relations
-
SEC filings
CEO
Neal F. Fowler
Country
USA
City
Morrisville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page